Please ensure Javascript is enabled for purposes of website accessibility

Report: China-Linked Hackers Targeted Coronavirus Vaccine Developer Moderna

By Eric Volkman – Jul 30, 2020 at 7:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The high-profile biotech says it has measures in place to guard against such attacks.

Sophisticated espionage is apparently occurring behind the scenes to acquire information on top coronavirus vaccine candidates.

On Thursday, Reuters reported that hackers linked to the Chinese government had targeted Moderna (MRNA 0.83%). Reuters cited an unnamed "U.S. security official" as its source. Moderna is considered by many observers to have the most promising vaccine candidate at the moment, mRNA 1273.

A hooded hacker using cellphones and a laptop.

Image source: Getty Images.

Moderna confirmed to Reuters that at some point earlier this year, the FBI alerted the company of possible "information reconnaissance activities" by a group of Chinese hackers. These activities cover a range of espionage activities, including the probing of online networks for vulnerabilities. It is not clear how successful they were, if at all, in their endeavors.

Apparently, these hackers include two unnamed Chinese citizens who were indicted last week for spying on the U.S. Among their targets were three companies -- again, unnamed -- involved in coronavirus research. One of the companies is a Massachusetts-headquartered biotech, which fits Moderna's profile.

Moderna spokesman Ray Jordan told Reuters that his company "remains highly vigilant to potential cybersecurity threats, maintaining an internal team, external support services, and good working relationships with outside authorities to continuously assess threats and protect our valuable information."

The article's source did not provide further details of the alleged hacking. The Chinese government has not yet commented on the report.

Moderna continues with its relatively rapid development of mRNA 1273, which utilizes messenger RNA to produce a response from the body's immune system. The vaccine candidate entered its phase 3 clinical trial on Monday.

Although a host of coronavirus vaccine candidates are in development, none have been approved for use.

Generating a disclosure failed. 504 Server Error: GATEWAY_TIMEOUT for url: https://www.fool.com/a/disclosure?uids=85296191&usernames=&tickers=NASDAQ%3AMRNA&serviceId=0&profile=usmf-free

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$119.06 (0.83%) $0.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.